AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31775808
Drug: Intra-substance injection
RxNorm normalized name: somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-substance injection with Diprospan (1 cc) and 1% xylocaine (1 cc)
Trial: 31775808
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (1 cc) and 1% xylocaine (1 cc)
Trial: 30572588
Drug: Daily substitution
RxNorm normalized name: hydroxypropyl cellulose, low substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily substitution of one portion of red meat with white meat, oily fish or white fish
Trial: 22791755
Drug: Low-dose pioglitazone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose pioglitazone (7.5 mg/d), flutamide (62.5 mg/d), and metformin (850 mg/d) (PioFluMet)
Trial: 16954331
Drug: Intravenous microdialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous microdialysis of N(G)-nitro-l-arginine methyl ester (l-NAME; NO synthase inhibitor) during local warming to 42 degrees C
Trial: 11914932
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg NSC‐631570
Trial: 11914932
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg gemcitabine/m2 followed by 20 mg NSC‐631570 weekly
Trial: 11914932
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg gemcitabine/m2
Trial: 1320917
Drug: Oral granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral granisetron 1.0 mg twice daily
Trial: 1320917
Drug: Oral granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral granisetron 0.25 mg twice daily
Trial: 1320917
Drug: Oral granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral granisetron 0.5 mg twice daily
Trial: 31470240
Drug: ECIG+OB (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECIG+OB (18 ng/ml nicotine)
Trial: 29756979
Drug: Glutamine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (10 g every 8 hours)
Trial: 25091553
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) infusion with standard treatment
Trial: 17623016
Drug: Indomethacin plus
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin plus statin (10 mg of rosuvastatin)
Trial: 26982282
Drug: Cream
RxNorm normalized name: Cream
DrugBank: Coffea arabica seed, roasted (DB15603)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream
Trial: 26060395
Drug: Dressing Gel
RxNorm normalized name: RADIAGEL WOUND DRESSING GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dressing Gel
Trial: 15122540
Drug: Piribedil (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piribedil (150 mg mean daily dose)
Trial: 9269062
Drug: Third dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third dose at 24 weeks
Trial: 3087091
Drug: Clenbuterol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clenbuterol (3 X 0.02 mg/d)
Trial: 24158846
Drug: Intracameral bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intracameral bevacizumab (1.25 mg, 50 µL)
Trial: 24158846
Drug: Placebo (balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (balanced salt solution, 50 µL)
Trial: 23107655
Drug: n-3PUFA (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3PUFA (1 g/day)
Trial: 19593146
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthesia (TIVA) with remifentanil and propofol (group TIVA)
Trial: 1890744
Drug: HLBI-VCAP (II)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLBI-VCAP (II) regimen (HLBI 3 x 10(6) units/day, twice a week)
Trial: 1890744
Drug: HLBI-VCAP (I)
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLBI-VCAP (I) regimen (HLBI 3 x 10(6) units/day, daily, 56 days)
Trial: 28264833
Drug: Anticoagulant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant treatment (AC)
Trial: 19124057
Drug: PRP-OMPC formulations
RxNorm normalized name: NEISSERIA MENINGITIDIS OMPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP-OMPC formulations (3microg or 6microg)
Trial: 19124057
Drug: PRP-T formulation
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP-T formulation (12microg)
Trial: 19124057
Drug: PRP-OMPC formulations
RxNorm normalized name: NEISSERIA MENINGITIDIS OMPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP-OMPC formulations
Trial: 19124057
Drug: PRP-OMPC formulation
RxNorm normalized name: NEISSERIA MENINGITIDIS OMPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP-OMPC formulation with the lowest concentration
Trial: 12020983
Drug: 17beta‐estradiol 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17beta‐estradiol 2 mg+norethisterone acetate 1mg (E2+NETA) daily
Trial: 12020983
Drug: Raloxifene HCl
RxNorm normalized name: raloxifene HCl
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene HCl 60 mg (Evista) daily
Trial: 11783305
Drug: Juanxiao Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Juanxiao Tablet (JXT)
Trial: 7540461
Drug: G-CSF (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (5 micrograms/Kg B.W.) administered after chemotherapy cycles as needed
Trial: 376883
Drug: Oral amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral amphotericin B 50 mg four times a day
Trial: 19038583
Drug: Diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac potassium (100 mg)
Trial: 17205440
Drug: Miltefosine, 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miltefosine, 2.5 mg/kg/day for 28 days
Trial: 17205440
Drug: Amphotericin B,
RxNorm normalized name: Amphotericin B, compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphotericin B, 45 mg/kg over 90 days
Trial: 3065355
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of mifepristone
Trial: 3065355
Drug: 450 mg
RxNorm normalized name: aspirin 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg of mifepristone
Trial: 28877312
Drug: Topical fluorouracil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fluorouracil, 5%, cream applied twice daily for 2 to 4 weeks (28 to 56 doses)
Trial: 28877312
Drug: Vehicle control
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control cream applied twice daily for 2 to 4 weeks (28 to 56 doses)
Trial: 28877312
Drug: Topical fluorouracil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fluorouracil, 5%, cream
Trial: 23578589
Drug: Selling drugs
RxNorm normalized name: marine non-gelling gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selling drugs
Trial: 12897732
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (estrogens, progestins, and their combination)
Trial: 11350672
Drug: Damp gauze
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Damp gauze (Group G)
Trial: 1305312
Drug: Etodolac 300
RxNorm normalized name: etodolac 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac 300 mg b.i.d.
Trial: 1305312
Drug: Piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 20 mg/day plus placebo
Trial: 3906106
Drug: Progesterone treatment
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone treatment (100 mg twice daily delivered in vaginal pessaries)
Trial: 26855018
Drug: Liraglutide (glucagon‐like
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (glucagon‐like peptide‐1 receptor agonist)
Trial: 24356862
Drug: Therapeutic drug
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring-based dose adaptation strategy
Trial: 21851293
Drug: Modified constraint-induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified constraint-induced movement therapy (modified CIMT) at home (n=7)
Trial: 21851293
Drug: Modified constraint-induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified constraint-induced movement therapy (modified CIMT) at clinic (n=7)
Trial: 24189085
Drug: 1.8 mg
RxNorm normalized name: menthol 1.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mg liraglutide
Trial: 20417856
Drug: 1.8 mg
RxNorm normalized name: menthol 1.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mg liraglutide vs Sitagliptin
Trial: 20417856
Drug: 1.2 mg
RxNorm normalized name: RNA 1.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mg liraglutide vs Sitagliptin
Trial: 20417856
Drug: Liraglutide (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (both doses)
Trial: 15694949
Drug: Fluvastatin, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin, 40 mg daily
Trial: 12672708
Drug: Whole tablet
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole tablet dietary supplement
Trial: 12672708
Drug: Crushed tablet
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed tablet dietary supplement
Trial: 10881002
Drug: Daunorubicin (DNR)
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daunorubicin (DNR) 25 mg/m(2), i.v., weekly, x4 (cumulative dose 100 mg/m(2))
Trial: 1571905
Drug: Accelerated superfractionated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated superfractionated radiation therapy using a concomitant boost twice‐a‐day schedule (BID); 180 cGy/fraction with a boost of 160 cGy/fraction BID, 3 days per week.
Trial: 1571905
Drug: Conventional once‐a‐day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional once‐a‐day (QD) fractionation to doses in excess of 6600 cGy.
Trial: 29282469
Drug: Esketamine 28
RxNorm normalized name: esketamine 28 mg nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine 28 mg
Trial: 29282469
Drug: Esketamine 56
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Esketamine 56 mg
Trial: 30401610
Drug: 24,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24,000 IU vitamin D3 plus 300 μg calcifediol/mo
Trial: 18042032
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of 2% lidocaine gel intrarectally 10 minutes before biopsy
Trial: 18042032
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of intrarectal 40% DMSO with lidocaine equal to that in the lidocaine gel 10 minutes before procedure
Trial: 11213851
Drug: Lamotrigine chewable
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine chewable dispersible tablets administered rectally
Trial: 11213851
Drug: Lamotrigine chewable
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine chewable dispersible tablets administered orally
Trial: 8101813
Drug: Buserelin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buserelin (20 micrograms, nasal spray, daily for 28 days)
Trial: 27501953
Drug: Flapless (FLS)
RxNorm normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flapless (FLS) immediate implant placement
Trial: 27501953
Drug: Flap-involving (F)
RxNorm normalized name: F-15599
DrugBank: F-15599 (DB16936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flap-involving (F) immediate implant placement
Trial: 23271103
Drug: Insulin levels
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin levels greater than 15 µU/mL
Trial: 23271103
Drug: Insulin levels
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin levels of 5 µU/mL to 15 µU/mL
Trial: 16183735
Drug: Self-administered treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered treatment (control group)
Trial: 12932604
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg/day for 8 weeks
Trial: 8667129
Drug: Supportive periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive periodontal treatment (SPT)
Trial: 1297876
Drug: Cardil, 240‐360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardil, 240‐360 mg/day
Trial: 1297876
Drug: Cordafen, 30‐60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cordafen, 30‐60 mg/day
Trial: 28039317
Drug: Subcutaneous interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon β‐1a (sc IFN β‐1a) three times weekly (tiw)
Trial: 28039317
Drug: Subcutaneous interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon β‐1a (sc IFN β‐1a) once weekly (qw)
Trial: 23446085
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment (DT)
Trial: 28039317
Drug: Subcutaneous interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon β‐1a (sc IFN β‐1a) tiw
Trial: 28039317
Drug: Subcutaneous interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon β‐1a (sc IFN β‐1a) qw and tiw
Trial: 25559065
Drug: BCQB 180μg
RxNorm normalized name: immunoglobulin G, human 180 MG/ML [GamaSTAN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCQB 180μg co-administered with paroxetine 20mg
Trial: 23817631
Drug: Biological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological treatment with infliximab
Trial: 23817631
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with sulfasalazine plus hydroxychloroquine
Trial: 21062337
Drug: Scalloped implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scalloped implant group (20 patients)
Trial: 21062337
Drug: Flat implant
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flat implant group (20 patients)
Trial: 18821458
Drug: Behavioral Therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Therapy for Depression in Drug Dependence (BTDD)
Trial: 16505753
Drug: Patient-Controlled Sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-Controlled Sedation (PCS) with propofol (20-mg boluses)
Trial: 16505753
Drug: Standard sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard sedation (control group) with continuous infusion of propofol
Trial: 7494655
Drug: Sucrose 50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose 50% (2 mL)
Trial: 7494655
Drug: Placebo (distilled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (distilled water, 2 mL)
Trial: 30447348
Drug: Povidone-iodine solution
RxNorm normalized name: POVIDONE-IODINE 1 g in 100 mL TOPICAL LIQUID [Loris Povidone-Iodine Solution]
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-iodine solution 10% for about 1 min
Trial: 22314101
Drug: Korean red
RxNorm normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean red ginseng extract (9 capsules per day for 3 months)
Trial: 22314101
Drug: Placebo (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (9 capsules per day for 3 months)
Trial: 14698828
Drug: Trichloroacetic acid
RxNorm normalized name: Trichloroacetic Acid
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trichloroacetic acid (TCA) after administration of danazol
Trial: 14698828
Drug: Trichloroacetic acid
RxNorm normalized name: Trichloroacetic Acid
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trichloroacetic acid (TCA) after administration of goserelin acetate
Trial: 11556125
Drug: Enteric-coated pellets
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated pellets containing 75 mg diclofenac sodium (A)
Trial: 11556125
Drug: Enteric-coated tablet
RxNorm normalized name: Walgreens Low Dose Aspirin 81mg Enteric-Coated Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated tablet with 50 mg diclofenac sodium (B)
Trial: 11556125
Drug: Capsule containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule containing 140 mg diclofenac resinate (C)
Trial: 11556125
Drug: Dispersible tablet
RxNorm normalized name: Aspirin 75 mg orodispersible tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispersible tablet containing 46.5 mg diclofenac acid (D)
Trial: 7798613
Drug: Topical retinaldehyde
RxNorm normalized name: retinaldehyde
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical retinaldehyde 1%
Trial: 7798613
Drug: Topical retinaldehyde
RxNorm normalized name: retinaldehyde
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical retinaldehyde 0.5%
Trial: 7798613
Drug: Topical retinaldehyde
RxNorm normalized name: retinaldehyde
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical retinaldehyde 0.1%
Trial: 10473959
Drug: Topical retinaldehyde
RxNorm normalized name: retinaldehyde
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical retinaldehyde 0.05%
Trial: 7798613
Drug: Topical retinaldehyde
RxNorm normalized name: retinaldehyde
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical retinaldehyde (0.5%, 0.1%, 0.05%)
Trial: 25622123
Drug: 380 mg
RxNorm normalized name: aspirin 380 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 380 mg naltrexone injection + weekly psychotherapy for 4 weeks
Trial: 10484048
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (only diet therapy)
Trial: 8564488
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular mass heparin (LMMH) (70 anti‐Xa units/kg b.w.)
Trial: 8564488
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular mass heparin (LMMH)
Trial: 1769130
Drug: Pyridostigmine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (2 mg/kg p.o.)
Trial: 30323055
Drug: Inhaled cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled cannabis (100 mg dose)
Trial: 23748474
Drug: Phenobarbitone (PB)
DrugBank: Phenobarbital (DB01174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbitone (PB) 10 mg/kg/day on day 1 followed by 5 mg/kg/day on days 2-5
Trial: 23748474
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose (control)
Trial: 20946161
Drug: Sildenafil (flexible-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (flexible-dose of 25, 50, or 100 mg)
Trial: 18783652
Drug: Intratumoral radiotracer
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intratumoral radiotracer administration (n=35)
Trial: 18783652
Drug: Peritumoral radiotracer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritumoral radiotracer administration (n=45)
Trial: 18783652
Drug: Intratumoral radiotracer
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intratumoral radiotracer administration
Trial: 18783652
Drug: Peritumoral radiotracer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritumoral radiotracer administration
Trial: 9372661
Drug: Lung-protective approach
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung-protective approach (LPA) with permissive hypercapnia (PHY), VT < 6 ml/kg, distending pressures above PEEP < 20 cm H2O, and PEEP 2 cm H2O above the lower inflection point on the static inspiratory P-V curve (P(FLEX))